Medical device industry stop using consumers as guinea pigs for your products

Rate this post

Another important factor is trained personnel, this entails the use of platforms for the development of molecules and formulas to prepare a vaccine to combat the pandemic.

Likewise, the deputy director of the UAEH Medical Service stressed that COVID-19 has represented a challenge for medicine, something that leads to changes in human behavior guided by scientific evidence and the mobilization of technology for the development of medicines and vaccines. , which must provide security for all people.

When will the pandemic end?

There is no exact date, it is unknown which will be the first vaccine to prevent this disease, therefore, “in this new normal, changes in human behavior and the acquisition of healthy lifestyles must be permanent in the population, with them we will be able to face new pandemic processes in better conditions”, indicated Hernández Pacheco.

Mexico in clinical trials of vaccine against COVID-19

Currently, Mexico is in Phase 3 clinical trials of CanSino’s vaccine against COVID-19. Since October, the first batch of doses from this laboratory has arrived in Mexico. The vaccine, called Ad5-nCoV, uses a weakened virus from the common cold to introduce genetic material from the coronavirus into the human body.

It was developed by the Beijing Institute of Biotechnology and Chinese biopharmaceutical company CanSino Biologics.

According to the Ministry of Foreign Affairs, between 10,000 and 15,000 Mexican volunteers over the age of 18 will participate in these tests. New shipments will also arrive to apply doses in several states of the Mexican Republic.

The first results of this stage are expected to be obtained by February of the following year. It should be noted that, if this vaccine shows its effectiveness and safety, Mexico will require 35 million doses.

Vaccines with greater effectiveness

  1. phase 3 testing the effectiveness of its formulas in humans. In recent weeks, two vaccines have been talked about, as they have achieved successful results during clinical trials.
  2. These are the vaccines from the Pfizer-BioNTech pharmaceutical company, which has more than 90% effectiveness, and the Moderna pharmaceutical company, with 94.5% effectiveness in preventing COVID-19.

Both investigations have made the world population think that by next year the vaccine could be ready to avoid contracting this disease, and thus end the pandemic and social distancing.

The main differences between these vaccines

Both require two doses to generate immunity against COVID-19 in the body, but Pfizer separates the applications by 21 days, while Moderna requires a space of 28 days between the first and second vaccinations.

The main differences between these vaccines As for its conservation, the Pfizer formula must be kept at minus 70 degrees Celsius; on the other hand, Moderna requires a temperature of minus 20 degrees Celsius. In addition, Pfizer’s resists five days under common refrigeration, while its competition resists up to 30 days in that state and can be 12 hours at room temperature.

This means that Pfizer’s doses are more difficult to transport, therefore their distribution would be reduced to reach hospitals, pharmacies and vaccination centers. Faced with this problem, the same pharmaceutical company Pfizer has designed a special box to transport its vaccine.

  1. Likewise, the price between the two is significant: the dose of Moderna will cost between 32 and 37 dollars, while Pfizer will cost 19.5 dollars.
  2. Finally, Pfizer invested $2 billion of its own funds for its research, while Moderna is part of the US government’s Operation Warp Speed ​​program and has received $2.5 billion to fund its scientific process.